Insider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) Insider Sells $1,145,039.80 in Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Francis Lo sold 51,004 shares of the company’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $22.45, for a total transaction of $1,145,039.80. Following the sale, the insider directly owned 237,688 shares in the company, valued at approximately $5,336,095.60. The trade was a 17.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Francis Lo also recently made the following trade(s):

• On Thursday, July 2nd, Francis Lo sold 44,838 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $22.59, for a total transaction of $1,012,890.42.
• On Thursday, June 4th, Francis Lo sold 39,741 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $17.49, for a total transaction of $695,070.09.
• On Wednesday, April 8th, Francis Lo sold 22,564 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $15.07, for a total transaction of $340,039.48.

Adaptive Biotechnologies Trading Down 3.2%

ADPT opened at $20.16 on Thursday. The firm has a market cap of $3.23 billion, a P/E ratio of -61.09 and a beta of 2.07. Adaptive Biotechnologies Corporation has a 12 month low of $9.96 and a 12 month high of $22.80. The stock has a 50-day moving average of $16.50 and a 200 day moving average of $15.96.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.03. The business had revenue of $70.87 million for the quarter, compared to the consensus estimate of $61.03 million. Adaptive Biotechnologies had a negative return on equity of 40.06% and a negative net margin of 16.82%.The company’s quarterly revenue was up 35.1% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.20) earnings per share. On average, research analysts forecast that Adaptive Biotechnologies Corporation will post -0.47 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have commented on ADPT shares. Guggenheim lifted their price objective on shares of Adaptive Biotechnologies from $21.00 to $22.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. Weiss Ratings restated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Monday, April 20th. JPMorgan Chase & Co. dropped their price target on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a research note on Wednesday, May 6th. BTIG Research reiterated a “buy” rating and set a $22.00 price target on shares of Adaptive Biotechnologies in a report on Wednesday, June 17th. Finally, TD Cowen increased their price objective on shares of Adaptive Biotechnologies from $19.00 to $21.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $20.50.

Institutional Trading of Adaptive Biotechnologies

Large investors have recently made changes to their positions in the stock. California State Teachers Retirement System increased its stake in Adaptive Biotechnologies by 1.0% in the 2nd quarter. California State Teachers Retirement System now owns 98,321 shares of the company’s stock worth $1,145,000 after buying an additional 933 shares during the period. PNC Financial Services Group Inc. lifted its holdings in Adaptive Biotechnologies by 6.8% during the 1st quarter. PNC Financial Services Group Inc. now owns 14,737 shares of the company’s stock valued at $205,000 after buying an additional 941 shares in the last quarter. Captrust Financial Advisors boosted its position in Adaptive Biotechnologies by 7.6% in the 2nd quarter. Captrust Financial Advisors now owns 15,762 shares of the company’s stock valued at $184,000 after buying an additional 1,119 shares during the period. Assetmark Inc. grew its stake in Adaptive Biotechnologies by 46.4% in the 1st quarter. Assetmark Inc. now owns 4,421 shares of the company’s stock worth $61,000 after acquiring an additional 1,401 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in Adaptive Biotechnologies by 26.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,419 shares of the company’s stock worth $120,000 after acquiring an additional 1,532 shares in the last quarter. 99.17% of the stock is owned by hedge funds and other institutional investors.

Adaptive Biotechnologies News Roundup

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Negative Sentiment: Harlan Robins sold 386,240 shares of Adaptive Biotechnologies, a transaction worth about $8.5 million, which is the most notable insider sale and may signal caution to investors. Article Title
• Negative Sentiment: Susan Bobulsky sold 487 shares, adding to a pattern of insider selling at Adaptive Biotechnologies. Article Title
• Negative Sentiment: Francis Lo sold 44,838 shares and separately sold another 51,004 shares, reinforcing the recent insider selling trend in ADPT. Article Title
• Neutral Sentiment: Recent filings note that these sales were made under pre-arranged 10b5-1 trading plans, which can reduce the significance of the transactions compared with discretionary selling.
• Positive Sentiment: Adaptive Biotechnologies previously posted better-than-expected quarterly results, including revenue growth of 35.1% year over year and EPS that beat estimates, which may help limit downside pressure.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.